Ampicillin dosage in meningoencephalitis
Reading File
Finding Sources
Finding Sources
Searching PubMed
ampicillin meningitis dosing
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Here is the synthesized answer:
Ampicillin Dosage in Meningoencephalitis
Ampicillin is used in meningoencephalitis primarily when Listeria monocytogenes is suspected or confirmed (e.g., in neonates, elderly, pregnant, or immunocompromised patients), as cephalosporins are inactive against Listeria.
Adults
| Source | Total Daily Dose | Dosing Interval |
|---|---|---|
| Adams & Victor's Neurology, 12e | 12 g/day IV | Every 4 hours (q4h) |
| Goldman-Cecil Medicine | 2 g IV every 4 hours (= 12 g/day) | q4h |
| Roberts & Hedges' Clinical Procedures | 8–12 g/day IV | Every 4 hours |
Standard adult dose: 2 g IV every 4 hours (12 g/day) for at least 3 weeks in Listeria meningitis. In critically ill patients, gentamicin is added (2 mg/kg loading dose, then 7.5 mg/kg/day divided every 8 hours). — Harrison's Principles of Internal Medicine 22e
Pediatric Dosing
| Age Group | Ampicillin Dose | Notes |
|---|---|---|
| Neonates 0–7 days | 100 mg/kg/dose q8h | + cefotaxime (50 mg/kg q8h) |
| Neonates 8–28 days | 75 mg/kg/dose q8h | + cefotaxime (may increase q8h) |
| Infants 4–12 weeks | Ampicillin + 3rd-gen cephalosporin | Covers Listeria + gram-negatives |
(Rosen's Emergency Medicine, 10e; Roberts & Hedges' Clinical Procedures)
For GBS meningitis in neonates ≤7 days: Penicillin G 250,000–450,000 units/kg/day in 3 divided doses; for >7 days: 450,000–500,000 units/kg/day in 4 divided doses (treat ≥14 days). — Harrison's 22e
Empiric Regimens by Age/Risk Group
| Patient Group | Includes Ampicillin? | Rationale |
|---|---|---|
| Neonates (0–4 wk) | ✅ Yes + cefotaxime or aminoglycoside | Covers Listeria, GBS, gram-negatives |
| Infants 4–12 wk | ✅ Yes + 3rd-gen cephalosporin | Listeria coverage |
| Adults 3 mo–50 yr | ❌ Not routinely | Pneumococcus/Meningococcus; ceftriaxone preferred |
| Elderly (>50 yr) / Immunocompromised | ✅ Yes + vancomycin + ceftriaxone | Listeria risk |
| Immunocompromised | ✅ Yes + vancomycin + ceftazidime | Broad + Listeria |
(Roberts & Hedges; Rosen's Emergency Medicine)
Penicillin-Allergy Alternative
Trimethoprim (10–20 mg/kg/day) + sulfamethoxazole (50–100 mg/kg/day) IV divided every 6 hours — reserved for penicillin-allergic patients with Listeria. — Harrison's 22e
Key Points
- Always administer IV — oral/IM routes produce inadequate CSF concentrations and are associated with treatment failure. — Adams & Victor's Neurology, 12e
- Ampicillin does not cover S. pneumoniae or N. meningitidis reliably; cephalosporins + vancomycin remain the backbone for community-acquired bacterial meningitis in non-Listeria-risk patients.
- Dexamethasone (10 mg IV q6h × 4 days, given 15–20 min before antibiotics) should be considered as adjunctive therapy to reduce neurologic sequelae. — Harrison's 22e
Amoebic meningoencephalitis treatment
Finding Sources
Finding Sources
Searching PubMed
amoebic meningoencephalitis treatment
Reading File
Reading File
Reading File
Reading File
Reading Article
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive, authoritative data from multiple major textbooks. Here is the complete synthesis:
Amoebic Meningoencephalitis — Treatment
"Amoebic meningoencephalitis" encompasses two distinct clinical syndromes caused by different free-living amoebae, plus CNS amebiasis from Entamoeba histolytica, each requiring different treatment.
1. Primary Amoebic Meningoencephalitis (PAM) — Naegleria fowleri
Character: Acute, fulminant, almost universally fatal. Onset 3–7 days after exposure to warm freshwater; death usually within 1 week.
Treatment (combination regimen — based on survivor case reports)
Do not wait for confirmation before starting treatment.
| Drug | Route | Notes |
|---|---|---|
| Amphotericin B (liposomal preferred) | IV (high-dose) | Drug of choice; N. fowleri highly susceptible in vitro |
| Miltefosine | Oral | Now commercially available (Impavido®); used successfully in PAM survivors; previously investigational |
| Azithromycin | IV/PO | Part of 5-drug combination |
| Fluconazole | IV/PO | Part of 5-drug combination |
| Rifampin | IV/PO | Part of 5-drug combination |
| Dexamethasone | IV | Adjunct — to control cerebral edema |
Based on analysis of the 4 US PAM survivors, the current recommended combination is: amphotericin B + azithromycin + fluconazole + miltefosine + rifampin, plus dexamethasone for cerebral edema. — Red Book 2021
- All six documented survivors worldwide received early diagnosis + high-dose amphotericin B + rifampin as the core. — Sherris & Ryan's Medical Microbiology, 8e
- CDC consultation is strongly advised (Tel: 770-488-7100); PCR confirmation available through CDC.
2. Granulomatous Amoebic Encephalitis (GAE) — Acanthamoeba spp.
Character: Subacute/chronic; primarily in immunocompromised hosts; weeks to months course; single or multiple ring-enhancing lesions on MRI.
Treatment (multidrug regimen; no established standard)
| Drug Category | Agents |
|---|---|
| Antiprotozoal | Pentamidine |
| Sulfonamide | Sulfadiazine or trimethoprim-sulfamethoxazole |
| Antifungal | Flucytosine (5-FC) + fluconazole or itraconazole |
| Macrolide | Azithromycin |
| Antiprotozoal (novel) | Miltefosine |
| Topical (skin lesions) | Chlorhexidine gluconate + ketoconazole |
Combination: pentamidine + an azole + a sulfonamide + flucytosine + miltefosine — Bradley & Daroff's Neurology; Red Book 2021
⚠️ Voriconazole is NOT active against Balamuthia (though active against Acanthamoeba).
3. Granulomatous Amoebic Encephalitis (GAE) — Balamuthia mandrillaris
Character: Subacute/chronic; affects both immunocompromised AND immunocompetent patients (including children); may be preceded by chronic skin lesions.
Treatment
| Drug | Notes |
|---|---|
| Pentamidine | Core agent |
| Sulfadiazine | Core agent |
| Fluconazole | Preferred azole (voriconazole NOT effective) |
| Azithromycin or clarithromycin | Macrolide component |
| Flucytosine | Part of combination |
| Miltefosine | Amebicidal in vitro; used in combination |
| Albendazole | Additional agent per some regimens |
| Surgical resection | Of CNS lesions where feasible — reported successful combinations include surgery + multidrug therapy |
Red Book 2021; Bradley & Daroff's Neurology, 7e
4. CNS Amebiasis — Entamoeba histolytica
Character: Rare complication of intestinal/hepatic amebiasis; brain abscess or meningoencephalitis via hematogenous spread from bowel.
Treatment
| Drug | Notes |
|---|---|
| Metronidazole | IV; primary treatment |
| Paromomycin | Luminal agent to eradicate intestinal carriage |
| Neurosurgical intervention | May be required for abscess |
Rosen's Emergency Medicine; Bradley & Daroff's Neurology
Summary Table
| Organism | Syndrome | Key Treatment |
|---|---|---|
| Naegleria fowleri | PAM (acute, fulminant) | AmB B + miltefosine + azithromycin + fluconazole + rifampin + dexamethasone |
| Acanthamoeba spp. | GAE (subacute, immunocompromised) | Pentamidine + sulfonamide + flucytosine + azole + miltefosine ± azithromycin |
| Balamuthia mandrillaris | GAE (subacute, any host) | Pentamidine + sulfadiazine + fluconazole + macrolide + flucytosine + miltefosine ± surgery |
| Entamoeba histolytica | CNS amebiasis (rare) | IV metronidazole + paromomycin ± neurosurgery |
Key Principles
- All three free-living amoeba syndromes carry extremely high mortality (>97% for PAM); treatment is largely empirical based on survivor reports.
- Early initiation of combination therapy without awaiting confirmation is critical for PAM.
- Antiprotozoal agents are largely ineffective as monotherapy — combination regimens are mandatory. — Adams & Victor's Neurology, 12e
- Miltefosine (Impavido®) is now commercially available in the US and represents the most important advance in recent years. — Haston & Cope, Curr Opin Infect Dis, 2023 [PMID: 37093056]
- Contact CDC Emergency Operations Center (770-488-7100) for real-time consultation on all suspected free-living amoeba CNS infections.
Benadryl syrup for dystonia
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I have all the information needed for a complete, well-cited answer.
Diphenhydramine (Benadryl) for Dystonia
Benadryl (diphenhydramine) is a first-line agent for acute drug-induced dystonia (acute dystonic reactions). It works via its anticholinergic properties — by blocking muscarinic M1 receptors on nigrostriatal medium spiny neurons, it counteracts the dopamine D2 antagonism caused by antipsychotics and other drugs (e.g., metoclopramide, prochlorperazine). — Goodman & Gilman's Pharmacological Basis of Therapeutics
Dosage
| Route | Dose | Onset |
|---|---|---|
| IV (preferred for acute) | 25–50 mg | Rapid; response expected within ~30 min |
| IM | 25–50 mg | Effective if IV access unavailable |
| Oral (PO) | 25–50 mg three to four times daily | Used for continuation/prophylaxis |
Rosen's Emergency Medicine; Tintinalli's Emergency Medicine; Goodman & Gilman's
Clinical Use
Indications for diphenhydramine in dystonia:
- Acute dystonic reactions from antipsychotics (haloperidol, chlorpromazine, etc.) or dopamine antagonists (metoclopramide, prochlorperazine)
- Oculogyric crisis (dystonic deviation of the eyes)
- Neck/tongue/jaw dystonia (torticollis, trismus) from drug exposure
- Dystonia prophylaxis when combining IM haloperidol with another agent (diphenhydramine is preferred in this setting due to its dual antihistamine + anticholinergic effect and added sedation) — Goodman & Gilman's
Key points:
- Highest risk population: young, antipsychotic-naïve patients, especially ages 10–19 — Goodman & Gilman's
- IV/IM diphenhydramine is equally effective as benztropine (1–2 mg) for acute dystonic reactions
- If no response within 1 hour → add lorazepam 1–2 mg IV, repeatable in 15–20 min — Rosen's Emergency Medicine
After Acute Treatment — Oral Continuation
Oral diphenhydramine 25–50 mg PO three to four times daily (or benztropine 1–2 mg PO twice daily) should be continued for 48–72 hours after parenteral treatment to prevent rebound dystonia, because the offending drug (e.g., antipsychotic) remains in the system for days. — Tintinalli's Emergency Medicine; Rosen's Emergency Medicine
Severe/Laryngeal Dystonia
In laryngeal dystonia (risk of airway compromise), parenteral administration (IM or IV) is mandatory — do not use oral. Immediate recognition and treatment with IM/IV benztropine (1–2 mg) or diphenhydramine 50 mg is essential. — Kaplan & Sadock's Comprehensive Textbook of Psychiatry
Alternative First-Line Agents
| Drug | Dose | Notes |
|---|---|---|
| Benztropine | 1–2 mg IM/IV | More anticholinergic, less sedating than diphenhydramine |
| Lorazepam | 1–2 mg IV | Second-line if no response at 1 hour |
| Diazepam | 5–10 mg IV | Alternative benzodiazepine |
Context: When NOT to Use
- Chronic/idiopathic dystonia (e.g., cervical dystonia, writer's cramp): diphenhydramine is not the treatment of choice; botulinum toxin injections and other agents are preferred — Harrison's 22e
- Diphenhydramine is specifically indicated for drug-induced (secondary) acute dystonic reactions
Att hepatitis
Finding Sources
Finding Sources
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.